Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II

Bibliographic Details
Main Authors:	Ana Sandoval-Rodriguez, Aldo Torre-Delgadillo, Juan Armendariz-Borunda
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Medicine
Subjects:	liver fibrosis MAFLD MASLD steatotic liver disease non-alcoholic steatohepatitis (NASH)
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1371720/full

Similar Items

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
by: Ana Sandoval-Rodriguez, et al.
Published: (2022-04-01)

Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
by: Qingfu Dong, et al.
Published: (2023-04-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
by: Yvonne Burmeister, et al.
Published: (2023-12-01)

Adding to the confusion in more than just the name
by: Jacob George
Published: (2023-10-01)

MAFLD and CKD: An Updated Narrative Review
by: Alessandro Mantovani, et al.
Published: (2022-06-01)

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
by: Gary Huang, et al.
Published: (2023-10-01)

Editorial: The NAFLD-MAFLD conundrum
by: Andrea Dalbeni, et al.
Published: (2023-09-01)

Identifying advanced MAFLD in a cohort of T2DM and clinical features
by: Ana Maria Sanchez-Bao, et al.
Published: (2023-02-01)

COVID-19 and MAFLD/NAFLD: An updated review
by: Ali Nowroozi, et al.
Published: (2023-03-01)

Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
by: Weiyi Qu, et al.
Published: (2021-10-01)

An Update in Epigenetics in Metabolic-Associated Fatty Liver Disease
by: J. Samael Rodríguez-Sanabria, et al.
Published: (2022-01-01)

From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
by: Alexandra Gatzios, et al.
Published: (2022-01-01)

Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseKey points
by: Guillaume Henin, et al.
Published: (2024-02-01)

Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice
by: Carlos Cuño-Gómiz, et al.
Published: (2023-11-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

<i>Moringa oleifera</i> Improves MAFLD by Inducing Epigenetic Modifications
by: C. Alejandra Monraz-Méndez, et al.
Published: (2022-10-01)

Predictive Modeling of MAFLD Based on Hsp90α and the Therapeutic Application of Teprenone in a Diet-Induced Mouse Model
by: Yuan Xie, et al.
Published: (2021-09-01)

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2021-10-01)

Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population
by: Andrea Dalbeni, et al.
Published: (2023-10-01)

Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)
by: Olga Estévez-Vázquez, et al.
Published: (2021-09-01)

Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
by: Damien Chua, et al.
Published: (2022-11-01)

The association between diverse serum folate with MAFLD and liver fibrosis based on NHANES 2017–2020
by: Jiacheng Cai, et al.
Published: (2024-03-01)

Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the pastKey points
by: Oyekoya T. Ayonrinde
Published: (2021-06-01)

Molecular Advances in MAFLD—A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis
by: Adrian Kołakowski, et al.
Published: (2022-09-01)

Targeting the Adipose Tissue–Liver–Gut Microbiota Crosstalk to Cure MASLD
by: Daniela Gabbia, et al.
Published: (2023-11-01)

NAFLD: Mechanisms, Treatments, and Biomarkers
by: Fatiha Nassir
Published: (2022-06-01)

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
by: Yan Huang, et al.
Published: (2022-01-01)

Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
by: Wesam Bahitham, et al.
Published: (2024-02-01)

Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
by: Christian Stoess, et al.
Published: (2023-08-01)

Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis
by: Nancy Magee, et al.
Published: (2022-12-01)

Salt-Intake-Related Behavior Varies between Sexes and Is Strongly Associated with Daily Salt Consumption in Obese Patients at High Risk for MASLD
by: Bianca Heller, et al.
Published: (2023-09-01)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
by: Andrea Boccatonda, et al.
Published: (2023-03-01)

Circadian Misalignment Rather Than Sleep Duration is Associated with MAFLD: A Population-Based Propensity Score-Matched Study
by: Weng Z, et al.
Published: (2021-01-01)

Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
by: Jingli Gao, et al.
Published: (2024-03-01)

Targeting nuclear receptors for NASH/MASH: From bench to bedside
by: Rohit A. Sinha
Published: (2024-03-01)

Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
by: Pietro Torre, et al.
Published: (2021-12-01)

Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)—A Review
by: Gracjan Różański, et al.
Published: (2021-07-01)

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
by: Joo Hyun Oh, et al.
Published: (2024-04-01)

Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease
by: Georg Semmler, et al.
Published: (2023-09-01)

Regulation of hepatic genes related to lipid metabolism and antioxidant enzymes by sodium butyrate supplementation
by: Kazue Honma, et al.
Published: (2020-09-01)